Proteinuria in preeclampsia: is it important? by Özkara, Attila et al.
256
ORIGINAL PAPER /  OBSTERICS
Ginekologia Polska
2018, vol. 89, no. 5, 256–261
Copyright © 2018 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.a2018.0044
Proteinuria in preeclampsia: is it important?
Attila Özkara1, Aşkı Ellibeş Kaya2, Alper Başbuğ2, Sabri Berkem Ökten3,  
Ozan Doğan4, Mete Çağlar5, Selahattin Kumru5 
1Department of Obstetrics and Gynecology,Giresun University Obstetrics and Pediatrics Training and Research Hospital,  
Giresun, Turkey 
2Department of Obstetrics and Gynecology, Duzce University Hospital, Duzce, Turkey 
3Department of Obstetrics and Gynecology, Başkent University Istanbul Health Practice and Research Center, Istanbul, Turkey 
4Department of Obstetrics and Gynecology, Health Sciences University, Sisli Hamidiye Etfal Research and Training Hospital,  
Istanbul, Turkey 
5Department of Obstetrics and Gynecology, Akdeniz University Faculty of Medicine, Antalya, Turkey
ABSTRACT
Objectives: Our aim is to evaluate the laboratory results and proteinuria levels of preeclamptic women and their relation-
ships to maternal and fetal outcomes.
Material and methods: One hundred preeclamptic pregnant women who gave birth in our clinic between 2013 and 
2015 were included in our study retrospectively. The data collected from the patients included gestational week, age, 
gravidity, parity, abortus history, blood pressure, biochemical parameters, delivery method, maternal hospitalization time, 
cesarean indication, complications, blood products required, plasmapheresis use and dialysis need. The details about the 
newborns were recorded retrospectively. The relationships between preeclampsia signs and maternal and neonatal out-
comes were analyzed. The protein amounts were analyzed via 24-hour collected urine analyses and spot urine analyses. 
Results: A statistically significant positive correlation was observed between neonatal intensive care unit needs and pro-
teinuria levels. Fetal growth restriction, respiratory distress syndrome and sepsis were observed as the level of proteinuria 
increased, but the result was not statistically significant. Eclampsia was observed only in patients with massive proteinuria, 
and it was statistically significant. An increase in cesarean sections, placental abruptions, antihypertensive drug needs and 
blood product replacement rates was observed as the amount of proteinuria increased in preeclamptic women, but the 
results were not statistically significant. 
Conclusions: The severity of preeclampsia cannot be determined by the level of proteinuria. However, when massive 
proteinuria is detected, the clinician should be more cautious about maternal and fetal complications.
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INTRODUCTION
Gestational hypertensive disorders are seen in 5–10 per-
cent of all pregnancies [1]. They are one of the most common 
complications seen in pregnancy and one of the most impor-
tant causes of perinatal mortality and morbidity [1]. Gestatio-
nal hypertensive disorders were first classified in 1972 by the 
American College of Obstetricians and Gynecologists (ACOG), 
and modified by the National High Blood Pressure Education 
Program Working Group in 1990 and 2000. According to 
this classification, the hypertensive disorders seen during 
pregnancy are chronic hypertension, gestational hyperten-
sion, preeclampsia superimposed upon chronic hypertension 
and preeclampsia-eclampsia [2–4]. 
Preeclampsia typically arises after 20 weeks of gestation 
and is diagnosed with a blood pressure reading of 140/90 or 
greater, measured on two separate times four hours apart, 
co-existing with proteinuria, or high blood pressure wi-
thout proteinuria but accompanied by thrombocytopenia, 
renal failure, impaired liver function, pulmonary edema 
and prodromal signs like visual and cerebral symptoms. 
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Preeclampsia is a multisystemic disorder in which decreased 
organ perfusion is seen secondary to an endothelial disor-
der and vasospasm, and it is peculiar to gravid humans. It’s 
a dynamic and progressive process. In these pregnancies, 
the risks of maternal-fetal mortality or severe morbidity are 
increased [5, 6].
Preeclampsia and eclampsia are responsible for 10–
15 percent of all maternal deaths worldwide due to obste-
tric complications [7]. Early diagnosis and taking necessary 
precautions can reduce the risks, especially in preventing 
eclamptic seizures, and thus reduce maternal-fetal morbi-
dity and mortality rates [8].
Proteinuria is a sign of glomerular damage. A +1 pro-
tein value with urine dipstick analysis, more than 300 milli-
grams (mg) of protein in a 24-hour collected urine sample, 
or a value of 0.3 milligrams/deciliter (mg/dL) or more of 
protein/creatinine is called proteinuria [1].
The quantitative analysis of the amount of protein in 
urine collected for 24 hours is the gold standard for the 
calculation of proteinuria. In cases in which immediate dia-
gnosis is needed or the laboratory tools are not adequate, 
spot urine sample analysis with a dipstick can still be used 
[3]. Although the amount of proteinuria is excluded from the 
factors determining the severity of preeclampsia, it still has 
an important role in the diagnosis of preeclampsia. In the 
literature, there are studies showing that massive proteinuria 
has negative effects — especially on fetal outcomes and also 
on maternal outcomes. Based on these studies, we aimed 
to evaluate the amount of proteinuria, the other laboratory 
results of patients during pregnancy and their fetal and 
maternal outcomes in our study.
MATERIAL AND METHODS
One hundred and thirty-two preeclamptic pregnant wo-
men who gave birth in our clinic between January 2013 and 
October 2015 were located. When a power analysis was 
done by taking the preeclampsia incidence as 7 percent, 
the number of patients needed was calculated to be 98 with 
80 percent power and 5 percent type 1 error. The files of the 
patients were evaluated retrospectively. The age range of 
the patients was 16 to 42 years old. Twelve patients who had 
chronic hypertension, diabetes mellitus, renal or hepatic 
disorders, thrombophilia, the presence of congenital ano-
malies diagnosed during pregnancy or multiple pregnancies 
were excluded, and the data of 20 patients could not be 
accessed. The data of 100 women was evaluated.
The preeclampsia  diagnosis and classification were 
made according to the criteria of the ACOG Task Force on 
Hypertension in Pregnancy 2013 criteria. 
Data collection started after ethics committee approval 
was obtained from Düzce University/Düzce/Turkey with 
decision number 2015/164.
The data collected from the women who were inclu-
ded in our study encompassed the gestational week, age, 
gravidity, parity, abortion history, blood pressure, bioche-
mical parameters, delivery method (normal vaginal birth 
or cesarean section), maternal hospitalization time, cesa-
rean indication, complications (placental abruption, acute 
renal failure, pulmonary embolism, intracranial hemorrhage, 
disseminated intravascular coagulation and liver subcap-
sular hematoma), blood products used, plasmapheresis 
use and dialysis use if needed. In addition, the data also 
included the details about the women’s newborns (their 
weight, height and gender, their apgar scores, their neo-
natal intensive care unit requirements and hospitalization 
time, and the presence or absence of intrauterine growth 
restrictions, as well as the occurrence of transient tachyp-
nea of the newborn, respiratory distress syndrome, sepsis, 
perinatal death and necrotizing enterocolitis). All of the data 
was recorded retrospectively. The relationships between 
preeclampsia signs and maternal and neonatal outcomes 
were analyzed. The amounts of protein were analyzed by 
24-hour collected urine analyses and spot urine analyses. The 
24-hour collected urine protein results were divided into 
three subgroups as 300–1,000 mg/day, 1,001–3,000 mg/day 
and more than 3,001 mg/day. These groups were named 
Group 1, Group 2 and Group 3, respectively. Proteinuria was 
observed in all diagnosed preeclampsia patients. 
A comparison between continuous variables with a nor-
mal distribution pattern was done via the independent 
samples t-test, while the Mann-Whitney U test was utilized 
with data that did not have a normal distribution pattern. 
Pearson’s correlation coefficient test was used to explore the 
relationship between continuous variables with a normal 
distribution, whereas Spearman’s rho correlation coefficient 
was used for those without a normal distribution and the 
Bonferroni test was calculated for subgroup analyses. Sta-
tistical analyses were carried out with SPSS for Windows 
version 22.0 statistical software (SPSS Inc., Chicago, Illinois, 
United States), and a p value of less than 0.05 was considered 
as statistically significant.
RESULTS
The mean of the 24-hour collected urine volume was 
2.432 mL/day (min-max: 1.240–3.010 mL); the mean of the 
protein amount in the urine was 2.342 mg/day (min-max: 
302–7342 mg); and the mean of the protein/creatinine was 
0.74 mg/dl (min-max: 0.31–5.6).
The patients’ demographic data is shown in Table 1. The 
relationship between the patients’ ages and protein amounts 
was statistically significant as verified by using a post-hoc test 
(p = 0.004). The mean age was lower in Group 3, and it was 
statistically significant. This negative relationship was confir-
med with correlation analysis as well (p = 0.006, r = –0.271).
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Massive proteinuria was observed in 35 percent of all the 
patients. Among those patients, 62.8 percent of them showed 
severe preeclampsia characteristics; while approximately one-
-third of them had preeclampsia with no severe characteri-
stics. Seventy-five percent of the non-severe preeclampsia 
patients had proteinuria levels of less than 3 grams (g)/day.
The correlation between proteinuria levels and all the 
other parameters of preeclamptic patients were seen in 
Table 2.
Among the hematologic parameters, there was an in-
crease in the Lactate dehydrogenase (LDH), blood urea ni-
trogen (BUN) and activated partial thromboplastin time 
(aPTT) values as the proteinuria levels increased, and this 
positive correlation was statistically significant. A positive 
correlation which was statistically significant was observed 
between the amount of proteinuria and BUN (r = 0.267, 
p = 0.007), LDH (r = 0.233, p = 0.002) and aPTT (r = 0.203, 
p = 0.043) (p < 0.05) (Tab. 2). There was a negative correlation 
between the amount of proteinuria in preeclamptic patients 
with the height of the newborn (r = –0.106), the weight of 
the newborn (r = –0.201), the apgar score (r = –0.154) and 
maternal hospitalization (r = –0.16), but none of these were 
statistically significant  (Tab. 2).
An increase was observed in cesarean sections 
(p = 0.561), abruptions of the placenta (p = 0.312), the need 
for antihypertensive treatment (p = 0.323), and blood and 
blood products replacement (p = 0.319) rates as the prote-
inuria levels increased in preeclamptic patients, but these 
values were not statistically significant. The amount of prote-
inuria had a positive correlation with the need for Neonatal 
Intensive Care Unit (NICU) care and was statistically signi-
ficant (p = 0.015), while the positive correlation with NICU 
indications like fetal growth restriction (p = 0.33), respiratory 
distress syndrome (p = 0.613) and sepsis (p = 0.065) rates 
was not statistically significant. Eclampsia was only observed 
in the group 3 patients, who had proteinuria levels greater 
than or equal to 3 g, and the relationship was statistically 
significant (p = 0.018) (Tab. 3). 
The cesarean section rates of patients in groups 1, 2 and 
3 were 87.5 percent, 75.7 percent and 85.7 percent, while 
normal vaginal birth rates for the same groups were found to 
be 14.3 percent, 24.3 percent and 14.3 percent, respectively 
(p = 0.451) (Table 3). The rates for fetal growth restriction 
were calculated as 3.6 percent, 8.1 percent and 14.3 per-
cent, respectively (p = 0.333). No dissemine intravascular 
coagulation (DIC), acute renal failure, pulmonary embolisms, 
intracranial hemorrhages, subcapsular hematomas, need for 
dialysis or perinatal mortality were detected.  
DISCUSSION
In the bulletin they published in 2013, the  ACOG re-
ported that preeclampsia can be diagnosed without prote-
inuria. The preeclampsia without proteinuria rate is about 
10 percent [9]. Many studies showed that high levels of 
proteinuria were highly related to fetal and maternal morbi-
dity [10–13]. In our clinic, we did not have any preeclampsia 
patients without proteinuria on the given dates, so no group 
was formed as “patients with no proteinuria or patients with 
proteinuria less than 300 mg.” The reason for that might be 
the accustomed strong coexistence of preeclampsia with 
proteinuria in most of the clinicians’ minds. Preeclamptic 
women with no proteinuria might be diagnosed and follo-
wed as gestational hypertension or chronic hypertension. 
This is one limitation of our study.
Thornton et al. mentioned an increase in cesarean sec-
tions, magnesium sulphate treatment and preterm birth rates 
Table 1.  Demographic data of preeclamptic women 
Proteinuria 300–1000 mg 
(n = 28, mean ± SD  min, max) 
Proteinuria 1000–3000 mg 
(n = 37, mean ± SD  min, max) 
Proteinuria  ≥ 3001 mg 
(n = 35, mean ± SD  min, max)  p 
Age 32.7 ± 6.12 30.2 ± 6.14 28.6 ± 5.6 0.006*
Gravida 3 (1–5) 2 (1–5) 1 (1–5) 0.14
Parity 2 (1–5) 2 (1–4) 1 (1–4) 0.10
Systolic Pressure 152.79 ± 9.28 150.03 ± 15.09 153.63 ± 20.08 0.61
Diastolic Pressure 93.86 ± 11.73 92.32 ± 10.67 96.69 ± 10.08 0.22
Platelet 234000 ± 91000 204000 ± 87000 243000 ± 112000 0.40
Weight of Newborn 2521 ± 640 2618 ± 690 2230 ± 732 0.054*
Week of Gestation 35.94 ± 2.45 36.18 ± 2.55 35.32 ± 3.18 0.43
Preeclampsia with severe 
characteristics 10 (% 35.7) 15 (% 40.6) 22 (% 62.8) 0.06
Preeclampsia without severe 
characteristics 18 (% 64.2) 22 (% 59.4) 13 (% 37.1) 0.07
* p < 0.05 indicates statistical significance. Patients were grouped into three according to proteinuria amount; Group 1: 300–1000 mg, Group 2: 1001–3000 mg, Group 
3:  ≥ 3001 mg
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Table 3. Proteinuria Level relation with Maternal Morbidity and Neonatal Outcomes
Proteinuria
300–1000 mg
(n = 28) 
Proteinuria 
1001–3000 mg
(n = 35) 
Proteinuria
≥ 3001 mg 
(n = 35) 
p 
Normal Vaginal Birth, n (%) 4 (14.3) 9 (24.3) 5 (14.3) 0.451
Cesarean Section, n (%) 24 (85.7) 28 (75.7) 30 (85.7) 0.561
Abruption of Placenta, n (%) 0 1 (2.7) 3 (8.6) 0.312
Blood Products Replacement, n (%) 1 (3.6) 1 (2.7) 4 (11.4) 0.319
Antihypertansive Treatment, n (%) 12 (42.9) 15 (40.5) 20 (57.1) 0.323
FGR, n (%) 1 (3.6) 3 (8.1) 5 (14.3) 0.333
RDS, n (%) 2 (7.1) 4 (10.8) 5 (14.3) 0.613
YDGT, n (%) 5 (17.9) 2 (5.4) 4 (11.4) 0.270
Sepsis, n (%) 5 (17.9) 12 (32.4) 16 (45.7) 0.065
NEC, n (%) 0 1 (2.7) 0 0.423
Neonatal Intensive Care Unit Need, n (%) 8 (28.6) 10 (27.0) 20 (57.1) 0.015*
Prematurity, n (%) 19 (67.9) 22 (59.5) 26 (74.3) 0.406
Eclampsia, n (%) 0 0 4 (11.4) 0.018*
HELLP, n (%) 0 2 (5.4) 0 0.329
* p < 0.05 statistically significant difference
Table 2. The correlation analysis between amount of proteinuria, demographic characteristics and laborotary findings
Proteinuria
300–1000 mg 
(n = 28)
Proteinuria
1000–3000 mg 
(n = 37)
Proteinuria
≥ 3001 mg 
(n = 35)
r p
Age (y), mean ± SD 32.7 ± 6.12 † 30.2 ± 6.14 28.6 ± 5.6† –0.27 0.006*
Systolic Pressure (mmHg), mean ± SD 152.79 ± 9.28 150.03 ± 15.09 153.63 ± 20.08 –0.02 0.61
Diastolic Pressure (mmHg), mean ± SD 93.86 ± 11.73 92.32 ± 10.67 96.69 ± 10.08 0.11 0.22
Gestational age (week), mean ± SD 35.94 ± 2.45 36.18 ± 2.55 35.32 ± 3.18 –0.11 0.43
Number of Parity, median(min-max) 2 (1–5)† 2 (1–4) 1 (1–4)† –0.21 0.03*
Maternal Hospitalization (d), 
median(min-max) 5.0 (2–8) 4.8 (2–9) 5.3 (2–17) 0.16 0.43
Newborn Weight (gr), mean ± SD 2521 ± 640 2618 ± 690 2230 ± 732 –0.20 0.054
Apgar Score (5.Mi) median(min-max) 10 (3–10) 10 (7–10) 9 (4–10) –0.15 0.39
Hemoglobin (gr/dl), mean ± SD 11.78 ± 1.56 11.33 ± 1.70 1.78 ± 1.98 0.80 0.51
Hematocrit (%), mean ± SD 34.28 ± 4.24 34.16 ± 4.67 35.00 ± 5.46 0.58 0.73
Platelet (mm3), mean ± SD 224.82 ± 91.84 204.86 ± 87.62 243.51 ± 112.31 0.29 0.22
AST (u/l), median(min-max) 42 (9–440) 31 (11–186) 26 (10–75) –0.28 0.41
ALT (u/l), median(min-max) 53 (5–699) 22 (4–179) 14 (4–54) –0.63 0.14
LDH (u/l), median(min-max) 224 (150–878)† 285 (147–831) 324 (168–722)† 0.23 0.002*
Bun (mg/dl), median(min-max) 8.95 (4.8–22.6)† 9.72 (5–18) 10.60 (5–18)† 0.26 0.007*
Kreatinin (mg/dl), median(min-max) 0.67 (0.44–1.25) 0.72 (0.43–1.25) 0.69 (0.44–1.09) 0.05 0.52
Prothrombin Time, median(min-max) 11.5 (9.4–13.7) 11.1 (9.1–14.3) 11.0 (8.3–16.1) –0.19 0.21
Active Partial Thromboplastin Time, 
median(min-max) 27.7 (21.0–36.4)
† 28.1 (20.4–32.6) 29.6 (22.5–47.9)† 0.20 0.04*
* p < 0.05 indicates statistical significance. Patients were grouped into three according to proteinuria amount; Group 1: 300–1000 mg, Group 2: 1001–3000 mg, Group 
3:  ≥ 3001 mg. 
Abb; year: (y), day, (d), minutes (min). 
†: p < 0.05 compared with controls (1-way ANOVA with Bonferoni multiple comparisons test)
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when the amount of proteinuria is measured as 500 mg/day. 
Chan et al. found a statistically significant relationship be-
tween proteinuria and maternal and fetal outcomes [9, 10].
Mi Jung Kim et al. observed a negative correlation be-
tween age and the amount of proteinuria, and this data 
shows concordance with our results. In our study, we also 
observed that as the age of the patient decreases, the amo-
unt of proteinuria increases. While the same study showed 
that the gestational week is significantly earlier at the time 
of diagnosis in massive proteinuria, we did not observe 
a statistically significant difference in our study. This study 
showed significantly high rates of retinal detachment and 
pleural effusion in patients with massive proteinuria, while 
in our study, we observed none of these complications. The 
same study also showed similar eclampsia rates between 
patients with massive vs. mild proteinuria [11]. Mateus et 
al. found no significant relationship between eclampsia 
and the amount of proteinuria in a recent study they did 
in 2017 [12]. However, in our study, eclampsia rates were 
significantly higher in patients with massive proteinuria. 
Mateus et al. also showed that massive proteinuria in pre-
eclamptic patients had a negative effect on fetal outcomes 
in their recent study. They observed a significant decrease in 
birth weight, birth week and apgar scores [13]. In our study, 
we also found a significant increase in the duration of stay 
in neonatal intensive care units in babies of patients with 
massive proteinuria. The birth weight was found to be low, 
but this result was not statistically significant. In a similar 
study in which a massive proteinuria level was measured as 
10 g / 24 hours, no significant difference was shown between 
subgroups in terms of maternal outcomes. In terms of fetal 
outcomes, respiratory distress syndrome and intravascular 
hemorrhage rates were detected to be higher, but statisti-
cally, they were not significant [14].
In cases with severe preeclampsia, the appropriate ap-
proach for 34 weeks and older gestational ages is immediate 
termination of the pregnancy, whereas for 34 weeks and 
younger gestational ages, termination of the pregnancy is 
needed if maternal or fetal stabilization cannot be mainta-
ined [1]. A systematic review states that protein amounts 
should not be used to determine clinical decisions [15]. 
However, many studies, such as those mentioned above, 
show that massive proteinuria has negative effects on fetal 
outcomes. The reason for that might be that clinicians are 
apprehensive about massive proteinuria which leads them 
to terminate pregnancies in a hurry.
Von Dadelszen et al. published their PIERS study in 2011, 
and it showed no difference in terms of fetal and maternal 
outcomes between patients with and without proteinuria. 
However, parallel to our results, an increase in negative fetal 
and perinatal outcomes was found in patients with +3 and 
+4 proteinuria in spot urine samples [16].
Even though spot urinary analysis and proteinuria calcu-
lations were performed, patients were grouped according 
to their protein amounts in urine collected over 24 hours 
because the false negative and positive rates can be high in 
spot analysis. It is known that the 24-hour urine collection 
method is the gold standard for the calculation of proteinu-
ria [17]. Because of long collection times and other difficul-
ties, in cases in which an immediate diagnosis is needed or 
the laboratory tools are not adequate, spot urine sample 
analysis can still be used [1]. In addition, other practical 
analysis tools such as albumin/creatinine rates, protein/cre-
atinine rates and 12-hour urine analysis are becoming more 
popular in the literature [18].
According to the The National Institute for Health and 
Care Excellence (NICE) 2010 guidelines, urinary retesting to 
evaluate proteinuria is not needed [19]. We also included 
the 24-hour urine protein results in our study which were 
collected just after the patients were diagnosed as having 
preeclampsia. The repeated test results were not included 
in our study.
There is no solid evidence about the threshold of prote-
inuria which classifies it as severe. Some studies identify the 
24-hour urine protein level threshold for severe proteinuria 
as being at least 3 g or more, and some identify it as 5 g or 
more in the literature [11, 20, 21]. Because only 6 percent 
of our patient population had a proteinuria level of at least 
5 g or more, in order to have an appropriate statistical ana-
lysis between groups, we identified the severe proteinuria 
threshold as 3 g.
In our study, 35 percent of the preeclamptic patients had 
massive proteinuria. Of these patients, 62.8 percent of them 
showed severe preeclampsia characteristics, and approxi-
mately one-third of them were followed as preeclampsia 
with no severe characteristics. In addition, 75 percent of 
patients who showed no severe preeclampsia features had 
proteinuria levels of less than 3 g/day. This data is similar to 
that in the literature [11].
A study by Bramham et al. showed an increase in the 
rates of gestational complications, low fetal birth weight and 
severe preeclampsia as the proteinuria levels increased and 
when the proteinuria levels were measured as 300 mg/day 
and 500 mg/day [22].
In our study, the severity of preeclampsia showed 
a positive correlation with the amount of proteinuria, but 
the results were not statistically significant. Preeclampsia 
severity cannot be determined by the level of proteinu-
ria. However, when massive proteinuria is detected, the 
clinician should be more cautious about maternal and fe-
tal complications. After the patient is stabilized, the birth 
should be planned in a center which is well-equipped and 
experienced in terms of a neonatal intensive care unit, and 
precautions should be taken to prevent eclamptic seizures.
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CONCLUSIONS
Maternal and neonatal complications increased with the 
proteinuria levels, but the association was not statistically 
significant.
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